BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs

This article describes the R package BOIN, which implements a recently developed methodology for designing single-agent and drug-combination dose-finding clinical trials using Bayesian optimal interval designs (Liu and Yuan 2015; Yuan, Hess, Hilsenbeck, and Gilbert 2016). The BOIN designs are novel "model-assisted" phase I trial designs that can be implemented simply and transparently, similar to the 3 + 3 design, but yield excellent performance comparable to those of more complicated, model-based designs. The BOIN package provides tools for designing, conducting, and analyzing single-agent and drug-combination dose-finding trials.

[1]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[2]  Guosheng Yin,et al.  Bayesian optimal interval design for dose finding in drug-combination trials , 2017, Statistical methods in medical research.

[3]  Ying Yuan,et al.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials , 2016, Statistics in medicine.

[4]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[5]  Satoshi Morita,et al.  BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes , 2018, Pharmaceutical statistics.

[6]  H. D. Brunk,et al.  Statistical inference under order restrictions : the theory and application of isotonic regression , 1973 .

[7]  Frank Bretz,et al.  MCPMod: An R Package for the Design and Analysis of Dose-Finding Studies , 2009 .

[8]  Ying Yuan,et al.  Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.

[9]  Ying Yuan,et al.  gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points , 2019 .

[10]  Fangrong Yan,et al.  Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials , 2017, Clinical Cancer Research.

[11]  Guosheng Yin,et al.  STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials , 2017, Statistics in medicine.

[12]  Ying Yuan,et al.  Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.

[13]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[14]  Ying Yuan,et al.  Comparative review of novel model‐assisted designs for phase I clinical trials , 2018, Statistics in medicine.

[15]  Ying Yuan,et al.  Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).